Sergliflozin etabonate (GW-869682X) 是一种有效的口服活性钠葡萄糖协同转运蛋白 (SGLT2) (SGLT2) 抑制剂。Sergliflozin etabonate 具有抗糖尿病和抗高血糖作用。Sergliflozin etabonate 显着降低糖尿病小鼠的非空腹血糖水平。Sergliflozin etabonate 具有用于糖尿病研究的潜力。
| 生物活性 | Sergliflozin etabonate (GW-869682X) is a potent and orally activesodium glucose cotransporter (SGLT2)inhibitor. Sergliflozin etabonate shows antidiabetic and antihyperglycemic effects. Sergliflozin etabonate significantly reduces non-fasting blood glucose levels in diabetic mice. Sergliflozin etabonate has the potential for the research of diabetes[1]. |
| IC50& Target[1] | |
体内研究
(In Vivo) | Sergliflozin etabonate (1、3、10、30 mg/kg；口服；一次) 以剂量依赖性方式显着降低 KK-Ay 小鼠的非空腹血糖水平[1]。
Sergliflozin etabonate (1.7、8.4、45.7 mg/kg饲料含有 0.001、0.005 和 0.025% sergliflozin etabonate；进食；每天服用，持续 9 周) 以剂量依赖的方式降低非空腹血糖水平并降低肝脏中的甘油三酯含量 在 KK-Ay 小鼠中[1]。
| Animal Model: | 14 weeks, Female KK-Ay mice[1] | | Dosage: | 1, 3, 10, 30 mg/kg | | Administration: | Oral; once | | Result: | Significantly reduced non-fasting blood glucose level with the reduction in blood glucose level at 2 h post dosing in the 1 mg/kg group, 3 mg/kg group, 10 mg/kg group, and 30 mg/kg group was 12, 15, 28, and 39%, respectively. |
| Animal Model: | 4 weeks, Female KK-Ay mice[1] | | Dosage: | 1.7, 8.4, 45.7 mg/kg in the 0.001, 0.005, and 0.025% sergliflozin etabonate | | Administration: | Fed, daily for 9 weeks | | Result: | Reduced non-fasting blood glucose level and decreased triglyceride content in the liver in a dose-dependent manner in diabetic control KK-Ay mice. |
|
| 分子量 | |
| Formula | |
| CAS 号 | |
| 运输条件 | Room temperature in continental US; may vary elsewhere. |
| 储存方式 | Please store the product under the recommended conditions in the Certificate of Analysis. |
m.cnreagent.com